Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Program performance. The incremental cost-effectiveness of evaluation and treatment of disease among a hypothetical cohort of 1 000 B-notification patients followed for 20 years. This table presents the outcomes for the active case finding component of the program, and lists the number of QALYs averted, the net cost, the number of cases averted, and the difference in the number of deaths among individuals with tuberculosis with and without active case finding, for three levels of the evaluation rate. All outcomes are discounted at a rate of three percent per year. Each row is computed by averaging 10 000 replications of a cohort of 1 000 individuals each, over a 20-year period; standard errors are given in parentheses.

From: Cost-effectiveness of tuberculosis evaluation and treatment of newly-arrived immigrants

Evaluation Rate Starting Rate Completion Rate QALYs Saved Net costs (1000s) Cases Averted TB Deaths Averted
45% - - 1.9 (0.09) -11 (0.5) 0.18 (0.02) 0.059 (0.003)
65% - - 2.9 (0.08) -16 (0.5) 0.26 (0.02) 0.089 (0.004)
85% - - 3.9 (0.08) -22 (0.5) 0.38 (0.02) 0.12 (0.003)